(Q50472613)

14 March 2018

title

Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. (English)

1 reference

14 March 2018

1 reference

W Stöhr

1

1 reference

14 March 2018

T Langer

2

1 reference

14 March 2018

A Kremers

3

1 reference

14 March 2018

S Bielack

4

1 reference

14 March 2018

A Lamprecht-Dinnesen

5

1 reference

14 March 2018

E Frey

6

1 reference

14 March 2018

J D Beck

7

1 reference

14 March 2018

German Late Effects Working Group in the German Society of Pediatric Oncology and Hematology

8

1 reference

14 March 2018

publication date

1 January 2005

1 reference

14 March 2018

published in

Cancer Investigation

1 reference

14 March 2018

volume

23

1 reference

14 March 2018

issue

3

1 reference

14 March 2018

page(s)

201-207

1 reference

14 March 2018

Cisplatin ototoxicity in children: a practical grading system.

cites work

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055951

Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055951

Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055951

Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055951

Late effects surveillance system for sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055951

Prevalence of hearing loss among children 6 to 19 years of age: the Third National Health and Nutrition Examination Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055951

cis-platinum ototoxicity in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055951

Hearing loss in children receiving cisplatin chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055951

cis-platinum ototoxicity in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055951

Ototoxicity of cisplatinum in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055951

Ototoxicity of preradiation cisplatin for children with central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055951

Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055951

Ototoxic and nephrotoxic effects of combined treatment with cis-diamminedichloroplatinum and kanamycin in the guinea pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055951

Reversible cisplatin ototoxicity in the albino guinea pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055951

Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055951

High-dose cisplatin treatment: hearing loss and plasma concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200055951

21 January 2018

Identifiers

DOI

10.1081/CNV-200055951

1 reference

14 March 2018

1 reference

14 March 2018